+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis



Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis



Multiple Sclerosis 18(8): 1081-1091



The complex pathogenesis of multiple sclerosis, combined with an unpredictable prognosis, requires identification of disease-specific diagnostic and prognostic biomarkers. To determine whether inflammatory proteins, such as neurofilament light chain, myelin oligodendrocyte glycoprotein and myelin basic protein, and neurodegenerative proteins, such as tau and glial fibrillary acidic protein, can serve as biomarkers for predicting the clinical subtype and prognosis of MS. Cerebrospinal fluid and serum samples were collected from patients with a diagnosis of clinically isolated syndrome (n = 46), relapsing-remitting MS (n = 67) or primary-progressive MS (n = 22) along with controls having other non-inflammatory neurological disease (n = 22). Western blot analyses were performed for the listed proteins. Protein levels were compared among different clinical subtypes using one-way analysis of variance analysis. The k-nearest neighbour algorithm was further used to assess the predictive use of these proteins for clinical subtype classification. The results showed that each of tau, GFAP, MOG and NFL protein concentrations differed significantly (p < 0.001) in multiple sclerosis clinical subtypes compared with the controls. Levels of the proteins also differed between the multiple sclerosis clinical subtypes, which may be associated with the underlying disease process. Classification studies revealed that these proteins might be useful for identifying multiple sclerosis clinical subtypes. We showed that select biomarkers may have potential in identifying multiple sclerosis clinical subtypes. We also showed that the predictive value of the prognosis increased when using a combination of the proteins versus using them individually.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 036496039

Download citation: RISBibTeXText

PMID: 22252467

DOI: 10.1177/1352458511433303


Related references

Vitamin D Binding Protein Isoforms and Apolipoprotein E in Cerebrospinal Fluid as Prognostic Biomarkers of Multiple Sclerosis. Plos One 10(6): E0129291, 2016

Label-Free LC-MS/MS Proteomic Analysis of Cerebrospinal Fluid Identifies Protein/Pathway Alterations and Candidate Biomarkers for Amyotrophic Lateral Sclerosis. Journal of Proteome Research 14(11): 4486-4501, 2016

Development of protein biomarkers in cerebrospinal fluid for secondary progressive multiple sclerosis using selected reaction monitoring mass spectrometry (SRM-MS). Clinical Proteomics 9(1): 9, 2012

Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiology of Disease 35(2): 117-127, 2009

Multiple sclerosis cerebrospinal fluid biomarkers. Disease Markers 22(4): 187-196, 2006

An Extensive Search for Autoantibodies to Myelin Basic Protein in Cerebrospinal Fluid of Non-Multiple-Sclerosis Patients: Implications for the Pathogenesis of Multiple Sclerosis. European Neurology 42(2): 95-104, 1999

An extensive search for autoantibodies to myelin basic protein in cerebrospinal fluid of non-multiple-sclerosis patients: implications for the pathogenesis of multiple sclerosis. European Neurology 42(2): 95-104, 1999

Cerebrospinal fluid and urinary biomarkers in multiple sclerosis. Acta Neurologica Scandinavica 128(5): 321-327, 2014

Identification of candidate predictive protein biomarkers by M2 proteomics for clinical onset and treatment efficacy of multiple sclerosis. Journal of Neuroimmunology 275(1-2): 24, 2014

Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis. Multiple Sclerosis 19(5): 543-552, 2013

Molecular biomarkers in cerebrospinal fluid of multiple sclerosis patients. Autoimmunity Reviews 14(10): 903-913, 2016

Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis. European Journal of Neurology 22(8): 1169-1175, 2016

Cerebrospinal fluid biomarkers of beta-amyloid metabolism in multiple sclerosis. 2013

Immunophenotyping of cerebrospinal fluid cells in multiple sclerosis: in search of biomarkers. JAMA Neurology 71(7): 905-912, 2014

Cerebrospinal fluid biomarkers in clinically isolated syndromes and multiple sclerosis. Proteomics. Clinical Applications 1(9): 963-971, 2007